Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Target antigen density may impact clinical response in patients with relapsed/refractory multiple myeloma undergoing treatment with elotuzumab and belantamab mafodotin

Francesca Albano, Sabrina Browning, Fangyong Li, Noffar Bar, Terri Parker, Tara Anderson, Erica Stevens, Jennifer VanOudenhove, Martin Matthews, Elan Gorshein, Jason Haldas, Ashita Talsania, Kert Sabbath, Stuart Seropian, Stephanie Halene, Fabiana Perna, Natalia Neparidze

Blood (2025) 146 (Supplement 1): 7578.

https://doi.org/10.1182/blood-2025-7578

Published: 2025

Journal Articles

Prognostic impact of cytogenetic abnormalities in aggressive T-cell lymphomas: Defining high-risk subgroups through conventional karyotyping.

Ahmad Kiwan, Autumn Diadamo, Jia Di Wen, Tariq Kewan, Alexa Siddon, Shalin Kothari, Iris Isufi, Stuart Seropian, Scott Huntington, Francesca Montanari, Mina Xu, Peining Li, Michael Girardi, Tarsheen Sethi, Francine Foss

Blood (2025) 146 (Supplement 1): 1759.

https://doi.org/10.1182/blood-2025-1759

Published: 2025

Journal Articles

Pentostatin/TBI conditioning for allogeneic transplantation in T-cell lymphomas

Cristian Taborda, Iris Isufi, Tarsheen Sethi, Noffar Bar, Lohith Gowda, Lynn Wilson, Michael Girardi, Kenneth Roberts, Stuart Seropian, Francine Foss

Blood (2025) 146 (Supplement 1): 2433.

https://doi.org/10.1182/blood-2025-2433

Published: 2025

Journal Articles

Concurrent TP53 loss-of-function and epigenetic modifier mutations as a potential predictor of chemoimmunotherapy failure in DLBCL & hgbl

Arjun Ravishankar, Iris Isufi, Scott Huntington, Stuart Seropian, Francine Foss, Tarsheen Sethi, Shalin Kothari

Blood (2025) 146 (Supplement 1): 7071.

https://doi.org/10.1182/blood-2025-7071

Published: 2025

Journal Articles

Aberrant circulating CD4+ CD26- T-cells in T-cell rich B-cell lymphomas: Diagnostic pitfall or biomarker?

Arjun Ravishankar, Pohan Chen, Mina Xu, Demetrios Braddock, Alexa Siddon, Iris Isufi, Scott Huntington, Stuart Seropian, Francine Foss, Shalin Kothari, Tarsheen Sethi

Blood (2025) 146 (Supplement 1): 7182.

https://doi.org/10.1182/blood-2025-7182

Published: 2025

Journal Articles

Outcome of an Urban Cohort of North American Adult T-Cell Leukemia/Lymphoma Patients

Haris Qureshi, Ahmad Kiwan, Francine M. Foss, Shalin Kothari, Scott F Huntington, Iris Isufi, Stuart Seropian, Tarsheen Sethi

Blood (2024) 144 (Supplement 1): 6421.

https://doi.org/10.1182/blood-2024-211850

Published: 2024

Journal Articles

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Blood (2023) 142 (Supplement 1): 2159.

https://doi.org/10.1182/blood-2023-187433

Published: 2023

Journal Articles

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Blood (2023) 142 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2023-189040

Published: 2023

Journal Articles

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Blood (2023) 142 (Supplement 1): 469.

https://doi.org/10.1182/blood-2023-182177

Published: 2023

Journal Articles

Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience

Ramzi Hamouche, Francine M. Foss, Sayeef Mirza, Mengyang Di, Iris Isufi, Noffar Bar, Lohith Gowda, Sarah Perreault, Kenneth Roberts, Stuart Seropian, Tarsheen Sethi

Blood (2023) 142 (Supplement 1): 2172.

https://doi.org/10.1182/blood-2023-189414

Published: 2023

Journal Articles

CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)

Tariq Kewan, Sayeef Mirza, Alexander B Pine, Yusuf Rasheed, Ramzi Hamouche, Etienne Leveille, George Goshua, Sean X Gu, Yuxin Liu, Jennifer Vanoudenhove, Noffar Bar, Natalia Neparidze, Francine M. Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred I Lee, Stuart Seropian

Blood (2023) 142 (Supplement 1): 2132.

https://doi.org/10.1182/blood-2023-187295

Published: 2023

Journal Articles

Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel

Abu-Sayeef Mirza, Alexander Pine, Yusuf Rasheed, Ramzi Hamouche, Etienne Leveille, George Goshua, Sean Gu, Yuxin Liu, Jennifer VanOudenhove, Noffar Bar, Natalia Neparidze, Francine M. Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred I Lee, Stuart Seropian

Blood (2022) 140 (Supplement 1): 10410–10412.

https://doi.org/10.1182/blood-2022-168374

Published: 2022

Journal Articles

Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy

Blood (2022) 140 (Supplement 1): 7086–7087.

https://doi.org/10.1182/blood-2022-168109

Published: 2022

Journal Articles

Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 7308–7310.

https://doi.org/10.1182/blood-2022-166325

Published: 2022

Journal Articles

Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis

Mengyang Di, Jessica B Long, Iris Isufi, Francine M. Foss, Stuart Seropian, Cary P Gross, Scott F. Huntington

Blood (2022) 140 (Supplement 1): 10818–10819.

https://doi.org/10.1182/blood-2022-164915

Published: 2022

Journal Articles

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Blood (2021) 138 (Supplement 1): 1791.

https://doi.org/10.1182/blood-2021-148497

Published: 2021

Journal Articles

Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-134948

Published: 2020

Journal Articles

High Doses of Targeted Radiation with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-134624

Published: 2020

Journal Articles

Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma

Sabrina L. Browning, MD, Terri L. Parker, MD, Noffar Bar, MD, Tara Anderson, PA, Madhav V. Dhodapkar, MBBS, Stuart Seropian, MD, Alfred Ian Lee, MD PhD, Thomas Prebet, MD PhD, Stephanie Halene, MD, Mina L. Xu, MD, Elan Gorshein, DO, JD, MPH, Ashita Talsania, MCRP, MBBS, Wajih Zaheer Kidwai, MD, David H. Witt, MD, Victor Chang, MD, Andrew Lischuk, MD, Wei Wei, MD PhD, Andrew Haims, MD, Natalia Neparidze, MD

Blood (2020) 136 (Supplement 1): 20–22.

https://doi.org/10.1182/blood-2020-136478

Published: 2020

Journal Articles

Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas

Megan Lee, BS, Molly Schiffer, PharmD, Iris Isufi, MD, Scott F. Huntington, MD MPH, Mina L. Xu, MD, Stuart Seropian, MD, Lohith Gowda, MD, Shalin K. Kothari, MD, Michael Girardi, MD PhD, Francine M. Foss, MD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-139790

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Target antigen density may impact clinical response in patients with relapsed/refractory multiple myeloma undergoing treatment with elotuzumab and belantamab mafodotin

Prognostic impact of cytogenetic abnormalities in aggressive T-cell lymphomas: Defining high-risk subgroups through conventional karyotyping.

Pentostatin/TBI conditioning for allogeneic transplantation in T-cell lymphomas

Concurrent TP53 loss-of-function and epigenetic modifier mutations as a potential predictor of chemoimmunotherapy failure in DLBCL & hgbl

Aberrant circulating CD4+ CD26- T-cells in T-cell rich B-cell lymphomas: Diagnostic pitfall or biomarker?

Outcome of an Urban Cohort of North American Adult T-Cell Leukemia/Lymphoma Patients

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience

CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)

Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel

Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy

Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma

Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered

High Doses of Targeted Radiation with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma

Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only